Early Clinical Outcomes Of A New Enhanced Monofocal Intraocular Lens (Emv, Rayner, Uk)
Published 2023 - 41st Congress of the ESCRS
Reference: PO0300 | Type: Free paper | DOI: 10.82333/zpsh-at65
Authors: Shafiq Rehman 1 , Alex Shortt 2 , Nabila Jones 2 , Amir Hamid 2 , Clare Odonnell* 2
1Eye Sciences,Optegra Eye Health Care,Yorkshire,United Kingdom, 2Eye Sciences,Optegra Eye Health Care,London,United Kingdom
Purpose
To report clinical outcomes including complications, post-operative visual acuity, and refractive outcome data after small incision phacoemulsification surgery with implantation of a Rayner RayOne EMV intraocular lens.
Setting
Optegra Eye Hospitals, UK
Methods
A retrospective audit of the clinical outcomes of 152 consecutive cataract patients (mean age 68+/-10 years) following implantation of an EMV IOL (Rayner, Worthing, UK) was carried out between June 2021 and March 2023. Either a targeted monovision or emmetropic distance outcome was planned. Data were recorded in an electronic medical record at up to 3 months post-operatively. Procedures were excluded from the visual analysis if they had reasons for guarded visual prognosis such as amblyopia or maculopathy.
Results
Results from 180 eyes were included for analysis. 98% of distance targeted eyes achieved UDVA 20/40 or better and 77% achieved UDVA 20/20 or better. 89% of eyes had a SEQ within ±1.00D of predicted target and 100% of patients targeted for a near monovision outcome achieved N8 or better.
Conclusions
Our early data show that the emerging clinical outcomes appear favourable for this cohort overall. Data collection and analysis are ongoing and final follow up data will be reported in due course.